News

Director/PDMR Shareholding
Director/PDMR Shareholding
November 8, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 06 November 2017, it purchased 20,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.17p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,217,431 equivalent to 18.71% of Proteome Sciences' total issued share capital.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
October 27, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
October 23, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520 and 193,100 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.075p per Ordinary Share (the “Purchase”) and on 20 October it purchased 119,636 ordinary shares of 1p each at a price of 3.15p per Ordinary Share. Following the Purchase, Vulpes has a total direct and indirect interest in 55,012,971 equivalent to 18.64% of Proteome Sciences' total issued share capital.

GCLP Accreditation and Trading Update
GCLP Accreditation and Trading Update
October 18, 2017

The Company is pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this should start being reflected early in 2018.

Commenting on this update Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said “We are working hard to establish Proteome Sciences as a successful services business and are beginning to see the benefits of the comprehensive restructuring and refocusing which was initiated earlier in the year. While we would have liked greater progress to date, revenues continue to grow well and we are witnessing a material increase in enquiry and engagement levels during the second half, particularly from the US.  We remain confident that this can be reliably converted into service-based revenues in the near to medium term and are pleased that increasing demand for our TMT® reagents continues to underpin our overall revenue growth and prospects.”

Block Admission Return
Block Admission Return
October 3, 2017

Proteome Sciences Block Admission Return.

Issue of Equity
Issue of Equity
September 1, 2017

Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”)  as payment for professional services.

Directorate Changes
Directorate Changes
August 1, 2017

Proteome Sciences (AIM:PRM), is pleased to announce the appointment of Dr Ursula Ney as a Non-executive Director of the Company, with immediate effect, replacing Professor William Dawson who is standing down after providing 20 years of valuable service to the Company.

Interim results for the six months ended 30 June 2017
Interim results for the six months ended 30 June 2017
July 25, 2017

Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:

“We are pleased to report that performance during the first six months of 2017 has been broadly in line with expectations, and revenues significantly ahead of the equivalent period in 2016 driven by strong growth in TMT® sales. This was achieved despite predictable disruption resulting from the consolidation of our laboratory capabilities in Frankfurt and the relocation of our head office to London; these activities increased our administrative expenses for the period compared with 2016 but are expected to generate cost savings from the second half of 2017 onwards....."

Notice of Results
Notice of Results
July 11, 2017

Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.

Stroke Diagnostic Presentation at EuroMedLab 2017 – Research Milestone Achieved
Stroke Diagnostic Presentation at EuroMedLab 2017 – Research Milestone Achieved
June 30, 2017

We are pleased to announce that Randox Laboratories Ltd, (“Randox”) presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.